样式: 排序: IF: - GO 导出 标记为已读
-
-
The Challenge of Assessing Remission and Relapse in ANCA Kidney Disease J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-03-13 Brix, Silke R.
No abstract available
-
Secular Trends in Incidence of Treated Kidney Failure in the United States J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-03-13 Mallory L. Downie, Bethany J. Foster
An abstract is unavailable.
-
Watering Collecting Duct Cysts: Are Aquaporin2+ Progenitors the Answer? J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-03-13 Mauricio Ostrosky-Frid, Vishal Patel
An abstract is unavailable.
-
Authors' Reply: Eculizumab Seems to be a Life Saver Even in Shiga Toxin-Related Hemolytic Uremic Syndrome J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-03-01 Garnier, Arnaud
No abstract available
-
Prioritizing Skills for Optimal Peritoneal Dialysis Care: A Focus Beyond Specialty J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-03-01 Sahutoglu, Tuncay
No abstract available
-
Assessment of Novel Therapeutics to Improve Access to Transplantation for Highly Sensitized Patients in a Shifting Clinical Landscape J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-03-01 Lan, James H.
No abstract available
-
Adenine Nucleotide Translocators Control Kidney Metabolism and Lipid Handling J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-03-01 Sugahara, Sho, Brooks, Craig R.
No abstract available
-
Heterogeneity of Distal Convoluted Tubule Cells J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-03-01 Murillo-de-Ozores, Adrián R., Chen, Lihe
No abstract available
-
-
Authors' Reply: Prioritizing Skills for Optimal Peritoneal Dialysis Care: A Focus Beyond Specialty J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-03-01 Ku, Elaine, McCulloch, Charles E., Copeland, Timothy P., Johansen, Kirsten L.
No abstract available
-
Eculizumab Seems to be a Life Saver Even in Shiga Toxin–Related Hemolytic–Uremic Syndrome J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-03-01 Pottokaran, Jaicy
No abstract available
-
-
Retraction: GQ5 Hinders Renal Fibrosis in Obstructive Nephropathy by Selectively Inhibiting TGF-β–Induced Smad3 Phosphorylation J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-02-27
No abstract available
-
Improving Community Care of Individuals with CKD J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-02-01 Lim, Cynthia Ciwei, Tay, Wei Yi
No abstract available
-
Authors' Reply: Platelet Count, Platelet Volume and CKD J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-02-01 Kore, Rajshekhar, Jadvani, Dharmik, Arthur, John M., Jain, Nishank
No abstract available
-
The Ip6k1 and Ip6k2 Kinases Are Critical for Normal Renal Tubular Function J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-02-06 Betül Haykir, Seraina Olivia Moser, Eva Maria Pastor-Arroyo, Udo Schnitzbauer, Zsuzsa Radvanyi, Isabel Prucker, Danye Qiu, Dorothea Fiedler, Adolfo Saiardi, Henning J. Jessen, Nati Hernando, Carsten A. Wagner
tasis is mostly unknown. We demonstrate in a renal cell line and in mice that Ip6k1 and Ip6k2 are critical for normal expression and function of the major renal Na+/Pi transporters NaPi-IIa and NaPi-IIc. Moreover, Ip6k1/2−/− mice also show symptoms of more generalized kidney dysfunction. Thus, our results suggest that IP6Ks are essential for phosphate metabolism and proper kidney function in mammals
-
-
Platelet Count, Platelet Volume, and CKD J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-02-01 Daungsupawong, Hinpetch, Wiwanitkit, Viroj
No abstract available
-
-
Age- and Race-Specific Changes in ESKD Incidence over Four Decades J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-01-30 Chyng-Wen Fwu, Paul W. Eggers, Jenna M. Norton, Debbie S. Gipson, Paul L. Kimmel, Ivonne H. Schulman, Kevin E. Chan, Kara Bennett, Susan R. Mendley
decades beginning in 1980. Growth in incidence slowed for most groups by 1993, and by 2006, the annual percent change (APC) in ESKD incidence had declined for all groups, except White adults, for whom rates continued to rise. By 2019, ESKD incidence among Black and White adolescents nearly returned to 1980 levels, but no other group achieved that degree of improvement. Nonetheless, the ESKD incidence
-
Prophylactic Phosphate Restriction: A Strategy to Mitigate AKI-Associated Complications J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-01-26 Ben-Dov, Iddo Z., Potruch, Assaf, Abbasi, Momen
No abstract available
-
Amiloride Reduces Urokinase/Plasminogen-Driven Intratubular Complement Activation in Glomerular Proteinuria J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-01-23 Gustaf L. Isaksson, Gitte R. Hinrichs, Henrik Andersen, Marie L. Bach, Kathrin Weyer, Rikke Zachar, Jan Erik Henriksen, Kirsten Madsen, Ida K. Lund, Géraldine Mollet, Claus Bistrup, Henrik Birn, Boye L. Jensen, Yaseelan Palarasah
lement and generates C3a and C5a in vitro/ex vivo in urine from healthy persons when exogenous, inactive, plasminogen, and complement factors are added. Amiloride inhibits uPA and attenuates complement activation in vitro and in vivo. In conditional podocin knockout (KO) mice with severe proteinuria, blocking of uPA with monoclonal antibodies significantly reduces the urine excretion of C3a and C5a
-
Pkd2 Deficiency in Embryonic Aqp2+ Progenitor Cells Is Sufficient to Cause Severe Polycystic Kidney Disease J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-01-23 Akaki Tsilosani, Chao Gao, Enuo Chen, Andrea R. Lightle, Sana Shehzad, Madhulika Sharma, Pamela V. Tran, Carlton M. Bates, Darren P. Wallace, Wenzheng Zhang
emonstrating that Pkd2 deletion in embryonic Aqp2+ progenitor cells (AP), but not in neonate or adult Aqp2+ cells, is sufficient to cause severe polycystic kidney disease (PKD) with progressive loss of intercalated cells and complete elimination of α-intercalated cells, accurately recapitulating a newly identified cellular phenotype of patients with ADPKD. Hence, Pkd2 is a new potential regulator critical
-
VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-01-23 Navdeep Tangri, Vandana S. Mathur, David A. Bushinsky, Gerrit Klaerner, Elizabeth Li, Dawn Parsell, Yuri Stasiv, Michael Walker, Donald E. Wesson, David C. Wheeler, Vlado Perkovic, Lesley A. Inker
CKD study randomized 1480 individuals with CKD and metabolic acidosis, across 320 sites to placebo or veverimer (a novel hydrochloric acid binder). The findings did not demonstrate the efficacy of veverimer in slowing CKD progression, but the difference in serum bicarbonate between placebo and drug arms was only approximately 1 mEq/L. Veverimer was safe and well tolerated. Background Metabolic acidosis
-
Role of Age and Competing Risk of Death in the Racial Disparity of Kidney Failure Incidence after Onset of CKD J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-01-23 Guofen Yan, Robert Nee, Julia J. Scialla, Tom Greene, Wei Yu, Fei Heng, Alfred K. Cheung, Keith C. Norris
rans had a 2.5-fold higher cumulative incidence of kidney failure, compared with White veterans, in any follow-up period from CKD onset. This disparity resulted from a combination of higher hazards of progression to kidney failure and lower hazards of competing-risk death in Black veterans. Both, in turn, were largely explained by the younger age at CKD onset in Black veterans, underscoring an urgent
-
cGAS Activation Accelerates the Progression of Autosomal Dominant Polycystic Kidney Disease J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-01-22 Miran Yoo, Jonathan C. Haydak, Evren U. Azeloglu, Kyung Lee, G. Luca Gusella
mechanistic link between the deficiency polycystin-1 and mitochondrial homeostasis and the activation of the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)/stimulator of the interferon genes (STING) pathway. Our data identify cGAS as an important mediator of renal cystogenesis and suggest that its inhibition may be useful to slow down the disease progression. Background Immune
-
Enriched Single-Nucleus RNA-Sequencing Reveals Unique Attributes of Distal Convoluted Tubule Cells J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-01-19 Su, Xiao-Tong, Reyes, Jeremiah V., Lackey, Anne E., Demirci, Hasan, Bachmann, Sebastian, Maeoka, Yujiro, Cornelius, Ryan J., McCormick, James A., Yang, Chao-Ling, Jung, Hyun Jun, Welling, Paul A., Nelson, Jonathan W., Ellison, David H.
Significance Statement High-resolution single-nucleus RNA-sequencing data indicate a clear separation between primary sites of calcium and magnesium handling within distal convoluted tubule (DCT). Both DCT1 and DCT2 express Slc12a3, but these subsegments serve distinctive functions, with more abundant magnesium-handling genes along DCT1 and more calcium-handling genes along DCT2. The data also provide
-
Urinary CD4+ T Cells Predict Renal Relapse in ANCA-Associated Vasculitis J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-01-17 Prskalo, Luka, Skopnik, Christopher M., Goerlich, Nina, Freund, Paul, Wagner, Leonie, Grothgar, Emil, Mirkheshti, Pouneh, Klocke, Jan, Sonnemann, Janis, Metzke, Diana, Schneider, Udo, Hiepe, Falk, Eckardt, Kai-Uwe, Salama, Alan D., Bieringer, Markus, Schreiber, Adrian, Enghard, Philipp
Significance Statement Early identification of patients at risk of renal flares in ANCA vasculitis is crucial. However, current clinical parameters have limitations in predicting renal relapse accurately. This study investigated the use of urinary CD4+ T lymphocytes as a predictive biomarker for renal flares in ANCA vasculitis. This study, including urine samples from 102 patients, found that the presence
-
Resistant Hypertension in Dialysis: Epidemiology, Diagnosis, and Management J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-01-16 Panagiotis I. Georgianos, Rajiv Agarwal
ion, the prevalence of apparent treatment-resistant hypertension is estimated to be between 18% and 42%. Owing to the lack of a rigorous assessment of some common causes of pseudoresistance, the burden of true resistant hypertension in the dialysis population remains unknown. What distinguishes apparent treatment-resistance from true resistance is white-coat hypertension and adherence to medications
-
Bridging the 13-Year Evidence Gap: A Time for Age-Inclusive Research J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-01-15 Oni, Louise, Smith, Rona, Salama, Alan D., Barratt, Jonathan, Trachtman, Howard, Saleem, Moin
No abstract available
-
Insurance Transitions from Employer-Based Insurance to Medicare and Waitlisting for Kidney Transplantation: Placing Marietta v. DaVita in Context J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-01-15 Joel T. Adler, Arnold E. Kuk, David C. Cron, Layla Parast, Syed Ali Husain
An abstract is unavailable.
-
Remembering Eberhard Ritz: A Clinician–Scientist Extraordinaire J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-01-11 Jochen Reiser, Martin Zeier
An abstract is unavailable.
-
Renal Mitochondrial ATP Transporter Ablation Ameliorates Obesity-Induced CKD J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-01-11 Anna Permyakova, Sharleen Hamad, Liad Hinden, Saja Baraghithy, Aviram Kogot-Levin, Omri Yosef, Ori Shalev, Manish Kumar Tripathi, Haitham Amal, Abhishek Basu, Muhammad Arif, Resat Cinar, George Kunos, Michael Berger, Gil Leibowitz, Joseph Tam
y acid oxidation to aerobic glycolysis, resulting in mitochondrial protection, cellular survival, and preservation of renal function. These findings provide new insights into the underlying mechanisms of obesity-induced CKD and have the potential to be translated toward the development of targeted therapeutic strategies for this debilitating condition. Background The impairment in ATP production and
-
Advancing Clinical Care through ASN Kidney Health Guidance J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-01-08 Sarah L. Sampsel, Deidra C. Crews
An abstract is unavailable.
-
Lipid Management and Interactions with Immunosuppressants in Patients Undergoing Kidney Transplant: Opinions and Prospects J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-01-01 Li, Yanqin, Luo, Fan, Gao, Qi, Su, Licong
No abstract available
-
-
Authors' Reply: Lipid Management and Interactions with Immunosuppressants in Kidney Transplant Patients: Some Opinions and Prospects J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-01-01 Bae, Sunjae, McAdams-DeMarco, Mara A.
No abstract available
-
Phosphate Restriction Prevents Metabolic Acidosis and Curbs Rise in FGF23 and Mortality in Murine Folic Acid–Induced AKI J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2024-01-04 Ahmad Kamal Hamid, Eva Maria Pastor Arroyo, Charlotte Calvet, Timothy D. Hewitson, Maria Lavinia Muscalu, Udo Schnitzbauer, Edward R. Smith, Carsten Alexander Wagner, Daniela Egli-Spichtig
that dietary Pi restriction markedly diminished the early rise in plasma FGF23 and prevented the rise in plasma Pi, parathyroid hormone, and calcitriol in mice with folic acid–induced AKI (FA-AKI). Furthermore, the study provides evidence for Pi-sensitive osseous Fgf23 mRNA expression and reveals that Pi restriction mitigated calciprotein particles (CPPs) formation, inflammation, acidosis, cardiac
-
-
Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-26 Vincenti, Flavio, Bestard, Oriol, Brar, Amarpali, Cruzado, Josep M., Seron, Daniel, Gaber, A. Osama, Ali, Nicole, Tambur, Anat R., Lee, Helen, Abbadessa, Giovanni, Paul, Jo-Anne, Dudek, Markus, Siegel, Ruby J., Torija, Alba, Semiond, Dorothée, Lépine, Lucie, Ternes, Nils, Montgomery, Robert A., Stegall, Mark
Significance Statement There is no standardized desensitization regimen for kidney transplant candidates. CD38, expressed by plasma cells, could be targeted for desensitization to deplete plasma cells producing alloantibodies and donor-specific antibodies. Few studies and case reports are available regarding the use of CD38 antibodies for desensitization in patients awaiting kidney transplant. This
-
SGLT2 Inhibition and Tubular Sodium Handling J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-22 Biff F. Palmer, Deborah J. Clegg
An abstract is unavailable.
-
Are Observational Reports on the Association of Dialysate Sodium with Mortality Enough to Change Practice? Perspective from the RESOLVE Study Team J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-14 Brendan Smyth, Rathika Krishnasamy, Meg Jardine, on behalf of the RESOLVE Study Global Team
An abstract is unavailable.
-
Predicting Outcomes in Nephrology: Lots of Tools, Limited Uptake: How Do We Move Forward? J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-13 Adeera Levin
An abstract is unavailable.
-
Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3–5: An Analysis of a Randomized Trial (RESCUE) J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-13 Pablo E. Pergola, Michael Davidson, Camilla Jensen, Amir A. Mohseni Zonoozi, Dominic S. Raj, Philip Andreas Schytz, Katherine R. Tuttle, Vlado Perkovic
ith inflammation and hyporesponsiveness to treatment with erythropoiesis-stimulating agents. This exploratory analysis of the RESCUE clinical trial found that among patients with CKD stage 3–5 and systemic inflammation, ziltivekimab treatment significantly increased hemoglobin (Hb) levels after 12 weeks compared with placebo. Ziltivekimab was also associated with significant increases in serum iron
-
Recentering Accountability for Disparities in Kidney Transplant Access J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-12 Husain, Syed Ali
No abstract available
-
Prognostic Models in Nephrology: Where Do We Stand and Where Do We Go from Here? Mapping Out the Evidence in a Scoping Review J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-12 Jet Milders, Chava L. Ramspek, Roemer J. Janse, Willem Jan W. Bos, Joris I. Rotmans, Friedo W. Dekker, Merel van Diepen
field of prognostic models for kidney patients and provide directions on how to proceed from here. We performed a scoping review of studies developing, validating, or updating a prognostic model for patients with CKD. We searched all published models in PubMed and Embase and report predicted outcomes, methodological quality, and validation and/or updating efforts. We found 602 studies, of which 30
-
The Improved Kidney Risk Score in ANCA-Associated Vasculitis for Clinical Practice and Trials J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-12 Sebastian Bate, Dominic McGovern, Francesca Costigliolo, Pek Ghe Tan, Vojtech Kratky, Jennifer Scott, Gavin B. Chapman, Nina Brown, Lauren Floyd, Benoit Brilland, Eduardo Martín-Nares, Mehmet Fethullah Aydın, Duha Ilyas, Arslan Butt, Eithne Nic an Riogh, Marek Kollar, Jennifer S. Lees, Abdülmecit Yildiz, Andrea Hinojosa-Azaola, Ajay Dhaygude, Stephen A. Roberts, Avi Rosenberg, Thorsten Wiech, Charles
(Harrell's C=0.779). In the development cohort of 959 patients, no additional parameters aiding the tool were detected, but replacing the GFR with creatinine identified an additional cutoff. The parameter interstitial fibrosis and tubular atrophy was modified to allow wider access, risk points were reweighted, and a fourth risk group was created, improving predictive ability (C=0.831). In the validation
-
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-12 Kaitlin J. Mayne, Natalie Staplin, David F. Keane, Christoph Wanner, Susanne Brenner, Vladimir Cejka, Johannes Stegbauer, Parminder K. Judge, David Preiss, Jonathan Emberson, Daniele Trinca, Rejive Dayanandan, Ryonfa Lee, John Nolan, Akiko Omata, Jennifer B. Green, David Z.I. Cherney, Lai Seong Hooi, Roberto Pontremoli, Katherine R. Tuttle, Jennifer S. Lees, Patrick B. Mark, Simon J. Davies, Sibylle
tion had clinically significant levels of bioimpedance-derived “Fluid Overload” at recruitment. Empagliflozin induced a prompt and sustained reduction in “Fluid Overload,” irrespective of sex, diabetes, and baseline N-terminal pro B-type natriuretic peptide or eGFR. No significant effect on bioimpedance-derived fat mass was observed. The effects of SGLT2 inhibitors on body water may be one of the contributing
-
Matrix Metalloproteinase-7 in Urinary Extracellular Vesicles Identifies Rapid Disease Progression in Autosomal Dominant Polycystic Kidney Disease J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-11 van Heugten, Martijn H., Blijdorp, Charles J., Arjune, Sita, van Willigenburg, Hester, Bezstarosti, Karel, Demmers, Jeroen A.A., Musterd-Bhaggoe, Usha, Meijer, Esther, Gansevoort, Ron T., Zietse, Robert, Hayat, Sikander, Kramann, Rafael, Müller, Roman-Ulrich, Salih, Mahdi, Hoorn, Ewout J. On behalf of the DIPAK Consortium
Significance Statement There is an unmet need for biomarkers of disease progression in autosomal dominant polycystic kidney disease (ADPKD). This study investigated urinary extracellular vesicles (uEVs) as a source of such biomarkers. Proteomic analysis of uEVs identified matrix metalloproteinase 7 (MMP-7) as a biomarker predictive of rapid disease progression. In validation studies, MMP-7 was predictive
-
Heterogeneous Treatment Effects of Intensive Glycemic Control on Kidney Microvascular Outcomes and Mortality in ACCORD J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-11 Vivek Charu, Jane W. Liang, Glenn M. Chertow, June Li, Maria E. Montez-Rath, Pascal Geldsetzer, Ian H. de Boer, Lu Tian, Manjula Kurella Tamura
al, considering three outcomes of interest—a composite kidney outcome (driven by macroalbuminuria), all-cause mortality, and first assisted hypoglycemic event. We demonstrate that the effects of intensive glycemic control vary with risk of kidney failure, as predicted by the kidney failure risk equation (KFRE). Participants at highest risk of kidney failure gain the largest absolute kidney benefit
-
Empagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-11 Veena S. Rao, Juan B. Ivey-Miranda, Zachary L. Cox, Julieta Moreno-Villagomez, Christopher Maulion, Lavanya Bellumkonda, John Chang, M. Paul Field, Daniel R. Wiederin, Javed Butler, Sean P. Collins, Jeffrey M. Turner, F. Perry Wilson, Silvio E. Inzucchi, Christopher S. Wilcox, David H. Ellison, Jeffrey M. Testani
reabsorption), a magnitude out of proportion to that expected with only inhibition of sodium–glucose cotransporter-2. This finding was not driven by an “osmotic diuretic” effect; however, several parameters changed in a manner consistent with inhibition of the sodium–hydrogen exchanger 3. The large changes in proximal tubular handling were acutely buffered by increased reabsorption in both the loop
-
Prostacyclin Mitigates Renal Fibrosis by Activating Fibroblast Prostaglandin I2 Receptor J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-08 Jing Li, Yi Guan, Yunyu Xu, Yingxue Cao, Qionghong Xie, Raymond C. Harris, Matthew D. Breyer, Limin Lu, Chuan-Ming Hao
f a PGI2 analog or selective PTGIR agonist after the acute injury ameliorated renal fibrosis. Our findings provide new insights into the role of PGI2 in kidney biology and suggest that targeting PGI2/PTGIR may be a potential therapeutic strategy for CKD. Background Prostanoids have been demonstrated to be important modulators to maintain tissue homeostasis in response to physiologic or pathophysiologic
-
Prognostic Biomarkers in Kidney Transplantation: A Systematic Review and Critical Appraisal J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-06 Marc Raynaud, Solaf Al-Awadhi, Kevin Louis, Huanxi Zhang, Xiaojun Su, Valentin Goutaudier, Jiali Wang, Zeynep Demir, Yongcheng Wei, Agathe Truchot, Antoine Bouquegneau, Arnaud Del Bello, Élodie Bailly, Yannis Lombardi, Mehdi Maanaoui, Alessia Giarraputo, Sofia Naser, Gillian Divard, Olivier Aubert, Mohammad Hassan Murad, Changxi Wang, Longshan Liu, Oriol Bestard, Maarten Naesens, John J. Friedewald
expert reviewers, the authors have identified all prognostic kidney transplant biomarkers and showed overall suboptimal study designs, methods, results, interpretation, reproducible research standards, and transparency. The authors also demonstrated for the first time that the limited number of studies challenged the added value of their candidate biomarkers against standard-of-care routine patient
-
Of Peritoneal Dialysis Access and Home Dialysis Accessibility J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-06 Jeffrey Perl, Isaac Teitelbaum, Robert R. Quinn
An abstract is unavailable.
-
Morphometric Approach to Different Nephron Segments J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-01 Sasaki, Takaya, Tsuboi, Nobuo
No abstract available
-
Dicarboxylic Acid Dietary Supplementation Protects against AKI J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-04 Anne C. Silva Barbosa, Katherine E. Pfister, Takuto Chiba, Joanna Bons, Jacob P. Rose, Jordan B. Burton, Christina D. King, Amy O'Broin, Victoria Young, Bob Zhang, Bharathi Sivakama, Alexandra V. Schmidt, Rebecca Uhlean, Akira Oda, Birgit Schilling, Eric S. Goetzman, Sunder Sims-Lucas
ch is responsible for breaking down fats, without adversely affecting mitochondrial function. DC8 is not only affordable and easy to administer but also effective. These encouraging findings suggest that DC8 could potentially be used to assist patients who are at risk of experiencing this type of kidney damage. Background Proximal tubules are rich in peroxisomes, which are damaged during AKI. Previous
-
Oral Sodium Bicarbonate and Bone Turnover in CKD: A Secondary Analysis of the BASE Pilot Trial J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-04 Kalani L. Raphael, Ronit Katz, Brett Larive, Cynthia Kendrick, Tamara Isakova, Stuart Sprague, Myles Wolf, Dominic S. Raj, Linda F. Fried, Jennifer Gassman, Andy Hoofnagle, Alfred K. Cheung, Joachim H. Ix
er markers and other hormones related to bone health in individuals with CKD who have normal to slightly reduced total CO2 (20–28 mEq/L). Sodium bicarbonate increased serum levels of α-klotho but had no significant effect on other bone health markers, including intact fibroblast growth factor-23 (iFGF-23), intact parathyroid hormone (iPTH), and bone-specific alkaline phosphatase (B-SAP). Further study
-
-
Authors' Reply: Cell Therapies in Diabetic Kidney Disease: Is It Time for Clinical Translation? J. Am. Soc. Nephrol. (IF 13.6) Pub Date : 2023-12-01 Perico, Norberto, Griffin, Matthew D., Casiraghi, Federica, Remuzzi, Giuseppe
No abstract available